Literature DB >> 29348806

Therapeutic Nanosystem Consisting of Singlet-Oxygen-Responsive Prodrug and Photosensitizer Excited by Two-Photon Light.

Yi Lin1, Xiao-Fang Jiang1, Xiangyan Duan1, Fang Zeng1, Bo Wu1, Shuizhu Wu1.   

Abstract

Using light as the sole stimulus and employing the generated singlet oxygen as a therapeutic agent and the trigger to activate chemo-drug release could serve as an elegant way to bring into full play the advantageous features of light and enhance therapeutic efficacy through a combination of chemotherapy and photodynamic therapy. Herein a liposomal drug system has been developed by embedding a fluorescent photosensitizer and a prodrug into phospholipid vesicles. Upon one- or two-photon light irradiation, the photosensitizer generates singlet oxygen, which removes the protecting group of the prodrug and subsequently causes the release of the active drug chlorambucil. With the combined action of O21 and chlorambucil, highly controllable cytotoxicity toward cancer cells was achieved. In addition, the fluorescent photosensitizer gives out fluorescent signal acting as the drug monitoring agent. This strategy may provide an efficient approach for cancer treatment and some useful insights for designing light-stimulated on-demand therapeutic systems.

Entities:  

Year:  2017        PMID: 29348806      PMCID: PMC5767894          DOI: 10.1021/acsmedchemlett.7b00394

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

Review 1.  Building biomedical materials using photochemical bond cleavage.

Authors:  Chunyan Bao; Linyong Zhu; Qiuning Lin; He Tian
Journal:  Adv Mater       Date:  2015-02-05       Impact factor: 30.849

2.  Photosensitizer drug delivery via an optical fiber.

Authors:  Matibur Zamadar; Goutam Ghosh; Adaickapillai Mahendran; Mihaela Minnis; Bonnie I Kruft; Ashwini Ghogare; David Aebisher; Alexander Greer
Journal:  J Am Chem Soc       Date:  2011-05-03       Impact factor: 15.419

3.  Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study.

Authors:  Josée Savard; Hans Ivers; Marie-Hélène Savard; Charles M Morin
Journal:  Cancer       Date:  2015-02-11       Impact factor: 6.860

4.  Rapid Light-Triggered Drug Release in Liposomes Containing Small Amounts of Unsaturated and Porphyrin-Phospholipids.

Authors:  Dandan Luo; Nasi Li; Kevin A Carter; Cuiyan Lin; Jumin Geng; Shuai Shao; Wei-Chiao Huang; Yueling Qin; G Ekin Atilla-Gokcumen; Jonathan F Lovell
Journal:  Small       Date:  2016-04-28       Impact factor: 13.281

5.  Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.

Authors:  C Barckhausen; W P Roos; S C Naumann; B Kaina
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

6.  Water-dispersible fullerene aggregates as a targeted anticancer prodrug with both chemo- and photodynamic therapeutic actions.

Authors:  Jianquan Fan; Gang Fang; Fang Zeng; Xiaodan Wang; Shuizhu Wu
Journal:  Small       Date:  2012-11-01       Impact factor: 13.281

7.  Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry.

Authors:  Moses Bio; Pallavi Rajaputra; Gregory Nkepang; Samuel G Awuah; Abugafar M L Hossion; Youngjae You
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

8.  Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy.

Authors:  Mingliang Fan; Xiaofei Liang; Zonghai Li; Hongyang Wang; Danbo Yang; Bizhi Shi
Journal:  Eur J Pharm Sci       Date:  2015-09-02       Impact factor: 4.384

9.  A drug-specific nanocarrier design for efficient anticancer therapy.

Authors:  Changying Shi; Dandan Guo; Kai Xiao; Xu Wang; Lili Wang; Juntao Luo
Journal:  Nat Commun       Date:  2015-07-09       Impact factor: 14.919

Review 10.  Chemophototherapy: An Emerging Treatment Option for Solid Tumors.

Authors:  Dandan Luo; Kevin A Carter; Dyego Miranda; Jonathan F Lovell
Journal:  Adv Sci (Weinh)       Date:  2016-05-24       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.